In-Depth Research on Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 - Pipeline Review, H1 2017

Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) - Pipeline Review, H1 2017 is a new market research publication announced by Reportstack. Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 (ENPP2) is an enzyme encoded by the ENPP2 gene. It stimulates migration of melanoma cells. It has a role in induction of parturition. It is involved in cell proliferation and adipose tissue development.

Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) pipeline Target constitutes close to 11 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II and Preclinical stages are 1 and 7 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Gastrointestinal, Respiratory, Central Nervous System, Immunology, Musculoskeletal Disorders, Cardiovascular, Genito Urinary System And Sex Hormones and Male Health which include indications Idiopathic Pulmonary Fibrosis, Breast Cancer, Fibrosis, Liver Fibrosis, Lung Cancer, Multiple Sclerosis, Systemic Sclerosis (Scleroderma), Acute Pain, Atherosclerosis, Benign Prostatic Hyperplasia, Brain Ischemia, Chronic Obstructive Pulmonary Disease (COPD), Chronic Pain, Inflammatory Bowel Disease, Melanoma, Metastatic Lung Cancer, Musculoskeletal Pain, Non-Alcoholic Steatohepatitis (NASH), Osteoarthritis Pain, Ovarian Cancer, Thyroid Cancer and Visceral Pain.

Complete report available @ Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 - Pipeline Review, H1 2017

The latest report Ectonucleotide PyrophosphatasePhosphodiesterase Family Member 2 - Pipeline Review, H1 2017, outlays comprehensive information on the Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

- The report provides a snapshot of the global therapeutic landscape for Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39)
- The report reviews Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies Mentioned

Eli Lilly and Company Galapagos NV Ribomic Inc

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

ReportstackMarket Research

###